NCT04253964 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04253964
Title	Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Wake Forest University Health Sciences
Indications	lung non-small cell carcinoma
Therapies	Cisplatin + Nab-paclitaxel + Pembrolizumab Atezolizumab + Carboplatin + Nab-paclitaxel Pembrolizumab Cemiplimab + Cisplatin + Pemetrexed Disodium Cemiplimab + Cisplatin + Paclitaxel Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium Cemiplimab + Cisplatin + Nab-paclitaxel Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Cemiplimab + Nab-paclitaxel Atezolizumab + Cisplatin + Nab-paclitaxel Atezolizumab Atezolizumab + Cisplatin + Paclitaxel Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Cemiplimab + Pemetrexed Disodium Cemiplimab Carboplatin + Cemiplimab + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Levine Cancer Institute	RECRUITING	Charlotte	North Carolina	28204	United States	Details
Wake Forest Baptist Comprehensive Cancer Center	RECRUITING	Winston-Salem	North Carolina	27157	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT04253964Clinical Trial Detail